Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Cos With Gnrh Antagonists And Hphmg

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (1)
Phase 4 (1)

Trial Status

Completed2
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06812559CompletedPrimary

Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome

NCT05738382Phase 2Unknown

Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures

NCT02738580Phase 4Completed

Follicular Steroid Genesis in Controlled Ovarian Stimulation

Showing all 3 trials

Research Network

Common Treatments

  • Cos With Gnrh Antagonists And Hphmg1
  • Bg21091
  • Cos With Gnrh Antagonists And Rfsh1
  • Gnrh Antagonist Cetrorelix1
  • Progesterone1

Active Sponsors

  • Instituto Valenciano de Infertilidad, IVI VALENCIA1
  • Bio Genuine (Shanghai) Biotech Co., Ltd.1
  • Roche Pharma AG1
  • El Shatby University Hospital for Obstetrics and Gynecology1

Top Investigators

Related Conditions

  • Assisted Reproductive Technology1
  • Infertility1
  • Polycystic Ovarian Syndrome1

Activity Timeline